Share This Page
Suppliers and packagers for generic pharmaceutical drug: NATAMYCIN
✉ Email this page to a colleague
NATAMYCIN
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Harrow Eye | NATACYN | natamycin | SUSPENSION;OPHTHALMIC | 050514 | NDA | Harrow Eye, LLC | 82667-012-05 | 1 BOTTLE, GLASS in 1 CARTON (82667-012-05) / 15 mL in 1 BOTTLE, GLASS | 2024-11-01 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers and packagers for generic pharmaceutical drug: NATAMYCIN
Natamycin Pharmaceutical Suppliers: Who Manufactures Natamycin API, Intermediate, and Finished Products?
Natamycin supply chains split into three procurement lanes: natamycin active pharmaceutical ingredient (API) and related intermediates; finished-goods sterile/non-sterile products (notably ophthalmic suspensions and creams); and contract manufacturing for topical sterile formats. Supplier coverage is largely regional, with a smaller set of global API producers and a broader set of regional finished-dose packagers and distributors.
Who are the natamycin API suppliers and manufacturers?
The natamycin (pimaricin) market is supplier-light at the API level relative to larger antifungals. Procurement typically targets natamycin powder/specification-grade material for oral, topical, and ophthalmic products, plus natamycin intermediates used in upstream crystallization/purification workflows.
Global API manufacturing landscape
Common supplier archetypes for natamycin:
- Producer of natamycin fermentation-derived material (upstream cultivation and isolation).
- Purifier and crystallization specialist (controls polymorph and particle size for formulation performance).
- Contract API re-packager (COA-driven supply, often without being the original fermenter).
What natamycin grades are typically supplied?
- API grade natamycin (for pharmaceutical formulation)
- Technical grade (used where pharma is not specified)
- Ophthalmic-suitable material (used by finished-dose manufacturers that qualify raw material by sterility/bio-burden pathway)
Where do natamycin ophthalmic products come from (finished dose suppliers)?
Natamycin ophthalmic use drives most finished-dose procurement visibility because product SKUs are tied to ophthalmology distribution networks and local regulatory listings.
Finished-goods supplier patterns
Finished natamycin products generally come from:
- Brand holders that contract local manufacturing and fill-finish.
- Generic and distributor-run ophthalmic product lines sourced from contract manufacturers.
- Hospital-and-clinic procurement channels for preservative-containing suspensions.
Ophthalmic formulation implications for suppliers
Supplier qualification often requires:
- Confirmed particle size distribution for suspension stability
- Extractables and leachables compatibility for containers
- Sterility assurance and microbial limits appropriate to ocular use (even for non-sterile topical suspensions, depending on the local label and route)
Which companies supply natamycin creams and topical antifungal products?
Topical natamycin availability is usually broader than ophthalmic-only listings, but supplier visibility is more fragmented because many contracts are regional and tied to distributor authorizations.
Topical natamycin supplier categories
- Contract manufacturers of topical creams and ointments (tube formats)
- Finished-dose packagers that standardize across multiple antifungal brands
- Local distributors who import pharma-grade bulk and perform final packaging under authorization
What intermediates or upstream inputs does natamycin supply require?
Natamycin is typically produced via fermentation and downstream purification. Supplier dependencies usually include upstream fermentation media components and purification consumables that can impact cost and lead time.
Upstream supply chain chokepoints
- Raw fermentation feedstock availability
- Downstream purification filters and crystallization consumables
- Particle-size control inputs that support suspension performance and consistent appearance
What natamycin contract manufacturing options exist for pharma companies?
Companies seeking scale or new dosage forms commonly use contract development and manufacturing organizations (CDMOs) for:
- Ophthalmic suspension fill-finish and packaging
- Cream/ointment compounding, filling, and labeling
- Scale-up of suspension stability strategy (wetting agents, viscosity modifiers, and container selection)
Contract manufacturing qualification focus
- GMP compliance for natamycin-specific batch traceability
- Validation of mixing and suspension uniformity
- Microbial control strategy aligned to ocular/topical specifications
What is the regulatory status of natamycin suppliers across major markets?
Supplier readiness is usually assessed against:
- Local GMP certifications for bulk and finished dose manufacture
- Availability of CoA, impurity profile, and stability data for natamycin bulk
- Compliance with pharmacopeial specification expectations in target markets
How regulators and customers evaluate natamycin suppliers
Procurement diligence typically checks:
- Batch consistency and impurity limits for natamycin API
- Stability indicating assays used by the supplier
- Sterility assurance pathway for ophthalmic formats
What patent or exclusivity factors affect natamycin supplier entry?
Natamycin is generally positioned as an older antifungal with mature manufacturing and formulation history in many jurisdictions. For procurement planning, the key impact of IP is not usually raw material manufacturing exclusivity, but whether specific finished-dose formulations, processes, or packaging are protected.
Where IP tends to influence supplier access
- Patents on specific formulation systems (viscosity, wetting agents, stabilizers)
- Patents on method-of-manufacture or particle-size control approaches
- Brand-proprietary ophthalmic suspension stability strategies
How many qualified natamycin suppliers exist and what is the sourcing risk?
Natamycin’s sourcing risk is generally tied to:
- Limited number of API manufacturers versus a wider finished-dose and distributor ecosystem
- Geographic concentration of fermentation and downstream purification capacity
- Batch-to-batch consistency requirements for ophthalmic suspensions
Procurement risk indicators
- Lead time volatility for API powder shipments
- Capacity constraints in upstream fermentation and downstream purification stages
- Long qualification timelines for ocular-grade raw material and fill-finish suppliers
What are typical natamycin finished dose launch scenarios for new entrants?
New entrants usually choose between:
- Sourcing generic natamycin finished doses through authorized channels
- Developing a reformulated product using qualified API from a vetted supplier
- Contracting development and manufacturing for a local regulatory filing
What delays entries most often
- Finished-dose stability and suspension uniformity development
- Container closure system compatibility for ophthalmic products
- Regulatory documentation alignment of supplier CoAs and impurity profiles
Natamycin supplier comparison: API vs finished-dose procurement
| Procurement lane | What you buy | Typical supplier type | Primary bottleneck | Best fit for |
|---|---|---|---|---|
| API | Natamycin powder/bulk | API manufacturer, purifier/crystallizer | Consistency, impurity profile, particle size | Formulators and generics developing in-house |
| Intermediate/upstream support | Fermentation-related inputs and purification consumables | Upstream suppliers | Supply continuity and batch reproducibility | Scaling existing products |
| Finished dose | Ophthalmic suspension, cream/ointment | Brand/generic finished-dose manufacturer, CDMO | Fill-finish, stability, regulatory alignment | Companies wanting faster market entry |
Key Takeaways
- Natamycin supply is split between a smaller API manufacturer set and a larger regional finished-dose and distributor ecosystem.
- Ophthalmic procurement drives the highest qualification rigor due to suspension stability and ocular-grade quality requirements.
- Supplier entry constraints are less about natamycin itself and more about formulation/process/IP protection, plus qualification timelines for raw material and fill-finish.
- Procurement risk concentrates in upstream fermentation and downstream purification capacity, where batch consistency is critical.
FAQs
- What qualifications are required for natamycin API to support ophthalmic suspensions?
- How do natamycin suppliers manage particle size and polymorph control for stable suspensions?
- Which finished-dose formats of natamycin are most sensitive to container closure system selection?
- What GMP documentation do procurement teams require from natamycin API and finished-dose suppliers?
- What are common lead-time drivers in natamycin API production and purification?
References
- No sources were provided in the prompt, and no supplier list can be produced without verifiable, citable data.
More… ↓
